Federal Circuit Ruling Opens New Patent Challenge Avenue for Life Sciences Companies
The U.S. Court of Appeals for the Federal Circuit's decision in Xencor Inc. case provides drugmakers with a new strategy to challenge patents by focusing on inadequate written descriptions in Jepson claims.